Omrix Biopharmaceuticals Provides Preliminary Third Quarter 2008 Results and Increases 2008 Product Sales Guidance

Business Wire, Oct 20, 2008

NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today provided preliminary unaudited product sales for the third quarter ended September 30, 2008 and increased its 2008 product sales guidance.

Preliminary Third Quarter 2008 Results

Preliminary total revenues for the third quarter 2008 amounted to $21.3 million, an increase of approximately 35% when compared to $15.8 million reported for the same period in 2007. Preliminary product sales for the third quarter 2008 amounted to $19.4 million, an increase of approximately 39% when compared to $14.0 million reported for the same period in 2007. Preliminary biosurgery and immunotherapy product sales for the third quarter 2008 amounted to $9.4 million and $10.0 million, respectively, representing an increase of approximately 38% and 39%, respectively when compared to $6.8 million and $7.2 million, respectively, for the third quarter of 2007.

The Company will announce its complete financial results for the third quarter ended September 30, 2008 and host its financial results conference call on November 6, 2008 after the close of the U.S. financial markets.

2008 Guidance

The Company is increasing its previously disclosed 2008 product sales guidance to $70.0 to $72.0 million from $68.0 million to $71.0 million, which represents expected annualized product sales growth of between approximately 35% and 39%, respectively, when compared with 2007 product sales of $51.9 million. In addition, the Company is reiterating that in 2008 it expects an increase in biosurgery product sales of approximately 75% when compared to 2007.

The Company's product sales guidance is based on the following key assumptions:

-- No acquisitions; and

-- Current biosurgery sales forecasts provided by Ethicon, Inc., a Johnson & Johnson Company.

About Omrix Biopharmaceuticals, Inc.

Omrix is a fully integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products. Omrix' biosurgery product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The Company's passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies, infectious diseases and potential biodefense applications. For more information, please visit www.omrix.com.

Safe Harbor Statement

This news release contains forward-looking statements. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the Company's filings with the Securities and Exchange Commission (SEC), including sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K as filed with the SEC on March 17, 2008, and the Company's most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect circumstances or events after the date of this news release.